Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injection shots are weekly, self-administered medicines that work with hormones your gut already produces to reduce appetite and slow digestion. In the UK, two are licensed for weight management in adults: tirzepatide (Mounjaro) and semaglutide (Wegovy). Both are prescription-only medicines, so a qualified prescriber must assess your suitability before any treatment begins. The decision you're actually making isn't simply 'should I try an injection?' — it's which one suits your health picture, what the evidence says, and whether the route you choose to access it is genuinely safe. This page walks through each of those questions plainly, using current clinical evidence and UK regulatory guidance.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Both licensed injection shots slow the rate at which your stomach empties after eating. That physical change, combined with hormonal signalling to the brain, reduces hunger across the day rather than simply blunting it at mealtimes. Wegovy (semaglutide) does this through a single pathway, mimicking the GLP-1 gut hormone. Mounjaro (tirzepatide) adds a second: it also activates GIP receptors, making it the only dual-agonist weight-loss medicine currently licensed in the UK.
Why does that distinction matter to you? In the SURMOUNT-5 trial (a direct head-to-head study published in the New England Journal of Medicine in 2025) tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. SURMOUNT-1 had already shown average body-weight reductions of around 20–21% at the 15mg dose. Those are meaningful differences, and NICE's appraisal of tirzepatide (TA1026) acknowledged indirect comparisons favour the dual-agonist approach. But bigger average numbers don't settle the question for every individual: tolerability, your medical history, and which medicine a prescriber considers appropriate for you all feed into the decision.
You can read more about how each medicine works on our weight loss injections overview page, which covers the mechanism in more depth.
Both medicines share a similar licensed starting point. The prescriber is looking at body mass index alongside your health history. For adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea, either medicine may be clinically appropriate. Lower BMI thresholds can apply for some ethnic backgrounds under current UK guidance, a prescriber familiar with NICE TA1026 and TA875 will factor that in.
BMI alone, though, is never the whole story. A prescriber assesses the complete picture: other medicines you take, your history of GI conditions, whether you're planning a pregnancy (both are not recommended during pregnancy or breastfeeding), and your readiness to combine treatment with changes to eating and activity. Under-18s are not within the licensed population for either medicine. For a closer look at the injection-by-injection specifics, the weight loss shot injections guide breaks down the licensed details for each.
One practical note: NHS access to these medicines exists but is phased, with strict eligibility criteria and, for many people, long waits. A private route through a regulated pharmacy is how most people who don't currently qualify for NHS treatment (or who don't want to wait) access these medicines legally.
Treatment doesn't begin at a therapeutic dose. Both medicines start low to let your system adjust, the first few weeks are about tolerability, not transformation. Doses are then increased at intervals set by your prescriber, and that titration schedule matters: moving too fast is one of the most common reasons people experience avoidable nausea. The guide on how many shots are involved gives a clear picture of the timeline most people can expect.
The mechanics of injecting are simpler than most people anticipate. Each pre-filled pen delivers one weekly dose into the fat under the skin, typically on the abdomen, thigh, or upper arm. Where exactly to inject (and how to rotate sites) is covered by your Patient Information Leaflet and our clinical team, not guesswork. Pens are stored in a refrigerator. When your order arrives through a regulated pharmacy, it comes in plain, unbranded packaging via tracked DPD delivery, so there's no drama at the door.
Side effects are real and worth knowing about before you start. The most common are gastrointestinal: nausea, loose stools, constipation, or indigestion, most often in the first days after a new dose. They typically settle. Seek urgent medical help for severe, persistent stomach pain that reaches into your back, that's the MHRA's documented signal for possible pancreatitis, however rare. The NHS tirzepatide medicines page carries a clear side-effect summary worth reading before you begin treatment.
Because these are prescription-only medicines, the route matters as much as the medicine itself. The MHRA has issued repeated warnings about fake pens sold on social media and through unverified online sellers, some contained insulin rather than the stated active ingredient, causing hospitalisations. Red flags include offers made without any clinical assessment, prices dramatically below the market range, or sellers promoting discount codes for prescription medicines. The MHRA's Yellow Card service at yellowcard.mhra.gov.uk is where you can report any suspect source.
A legitimate online pharmacy for prescription medicines is registered with the General Pharmaceutical Council (GPhC). You can verify any pharmacy's registration status at the GPhC register before you commit to anything. At nume, our GPhC-registered prescribers personally review every consultation, a named clinician reads your answers, not automated software. If you're researching a specific treatment and want to understand how the m injection for weight loss works in practice, including what the titration schedule and clinical oversight involve, that page covers it in detail. For a plain breakdown of what the cost picture looks like across the private market, the cheap weight loss injections page covers what different price points do and don't include.
If you'd like to understand what clinical oversight looks like at nume specifically, our clinical team profile is worth a read. Ready to see whether you're a suitable candidate? Start your free consultation and a GPhC-registered prescriber will review your details the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.